In the updated results of Part D of the RELATIVITY-020, an open-label Phase I/II study, the combination of relatlimab plus nivolumab demonstrated similar clinical activity, albeit lower than the first-line setting, in patients with advanced melanoma who had previously failed to respond to one or more anti-PD-1 or anti-PD-L1-containing therapies, with ORRs of 12.0% and 9.2%, respectively (unpublished data) [59••]. This evidence concerns the gene PDCD1 and melanoma.